Pharmaceuticals

Cardiotonic Agents Market Anticipated to Reach $5.56 Billion by 2030

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Cardiotonic Agents Market Projected To Become By 2030 Based On Its 2026 Valuation?

The cardiotonic agents market has experienced substantial growth in recent years. Its valuation is projected to climb from $3.11 billion in 2025 to $3.5 billion by 2026, at a compound annual growth rate (CAGR) of 12.3%. This historical expansion can be attributed to several factors, including the rising incidence of heart failure, the reliance on inotropic support in critical care, limited alternatives for acute cardiac output improvement, the expansion of cardiac surgery procedures, and the prevalent hospital-centric cardiovascular treatment.

The market for cardiotonic agents is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $5.56 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.3%. The expansion observed during the projection period stems from factors such as a globally aging populace, a rise in advanced heart failure instances, the need for fast-acting cardiac medications, the enlargement of critical care facilities, and enhanced monitoring within cardiac intensive care units. Key trends anticipated during this period encompass the sustained application of cardiotonic medications for acute heart failure, a preference for administering these intravenously in hospital settings, a consistent requirement for digitalis glycosides in treating arrhythmia, the incorporation of cardiotonic agents into surgical cardiac management, and a progressive move towards combined cardiovascular treatment approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24184&type=smp

What Primary Drivers Are Shaping The Development Of The Cardiotonic Agents Market?

The increasing occurrence of cardiovascular diseases is anticipated to boost the expansion of the cardiotonic agents market in the future. Cardiovascular diseases (CVDs) encompass a range of conditions impacting the heart and blood vessels, such as coronary artery disease, heart failure, arrhythmias, and stroke. This increase in CVDs largely stems from poor dietary choices, particularly diets rich in saturated and trans fats, salt, and sugars, leading to issues like obesity, high blood pressure, and increased cholesterol. Cardiotonic agents enhance the heart muscle’s efficiency and contractile force, consequently promoting improved blood circulation and alleviating symptoms across different cardiovascular conditions. For example, data from September 2023, provided by the World Health Organization (a Switzerland-based intergovernmental body), indicated that cardiovascular diseases were responsible for 17.9 million deaths. Consequently, the growing prevalence of cardiovascular diseases is fueling the development of the cardiotonic agents market.

What Segment Groups Are Identified Within The Cardiotonic Agents Market?

The cardiotonic agents market covered in this report is segmented –

1) By Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, Other Drug Types

2) By Route Of Administration: Oral, Intravenous, Other Route Of Administrations

3) By Dosage Form: Tablet, Solution, Other Dosage Forms

4) By Application: Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, Other Applications

5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Digitalis Glycoside: Digoxin, Digitoxin, Lanatoside C

2) By Phosphodiesterase Inhibitors: Milrinone, Enoximone, Amrinone

3) By Cardioprotectants: Coenzyme Q10, Dexrazoxane, Trimetazidine

4) By Sympathomimetic Agents: Dobutamine, Dopamine, Norepinephrine

5) By Other Drug Types: Levosimendan, Omecamtiv Mecarbil, Cilostazol

What Trends Are Advancing Progress In The Cardiotonic Agents Market?

Leading companies in the cardiotonic agents market are concentrating on creating novel products, such as short-term inotropic drugs, to enhance cardiac performance in acute heart failure and cardiogenic shock. These short-term inotropic medications are designed to temporarily improve the heart’s ability to contract, thereby boosting cardiac output. As an illustration, in June 2023, Hikma Pharmaceuticals plc, a pharmaceutical company based in the UK, launched Dobutamine Injection, USP, supplied in a 250 mg/20 mL vial. This injection is utilized for short-term inotropic support in adults experiencing cardiac decompensation due to diminished heart contractility, frequently stemming from heart disease or post-cardiac surgery. Its mechanism involves stimulating beta-1 receptors, which enhances heart muscle contractility and cardiac output, with a rapid onset observed within 1–2 minutes. The injection is administered intravenously and is typically given within a hospital setting under close observation.

Which Companies Hold Significant Positions In The Cardiotonic Agents Market?

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

Read the full cardiotonic agents market report here:

https://www.thebusinessresearchcompany.com/report/cardiotonic-agents-global-market-report

How Does The Cardiotonic Agents Market Perform Across Major Global Regions?

North America was the largest region in the cardiotonic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cardiotonic Agents Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24184&type=smp

Browse Through More Reports Similar to the Global Cardiotonic Agents Market 2026, By The Business Research Company

Cardiovascular Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report

Inotropic Agents Market Report 2026

https://www.thebusinessresearchcompany.com/report/inotropic-agents-global-market-report

Cardiovascular Monitoring And Diagnostic Devices And Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/cardiovascular-monitoring-and-diagnostic-devices-and-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795